Dynavax Technologies Corp (DVAX)

[J_Cali]

Two Issues, Two perspectives to consider the data in context


Excluding overdose deaths, there were 20 (0.21%) deaths in subjects who received HEPLISAV-B and 7 (0.18%) in subjects who received Engerix-B. ...percentage wise fairly balanced and no time correlation to vaccination

Using population-based databases in HBV-23, in the HEPLISAV-B group, age-, sex-, and race- adjusted incidence rates of observed composite MACE outcomes and cardiovascular deaths were lower than expected, and myocardial infarction and strokes were similar to expected. In the Engerix-B group, observed composite MACE outcomes, deaths, myocardial infarctions, and strokes were each lower than expected. Notably, in HBV-23, the observed rate of myocardial infarction in the Engerix-B group was 6.8-fold lower than expected.

Expecting =>2/3 votes yes for safety